Efficacy and safety of Mylotarg (gemtuzumab ozogamicin) as salvage treatment in children with refractory or relapsed acute myeloid leukemia.

Trial Profile

Efficacy and safety of Mylotarg (gemtuzumab ozogamicin) as salvage treatment in children with refractory or relapsed acute myeloid leukemia.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2009

At a glance

  • Drugs Gemtuzumab ozogamicin (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Mar 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top